HR070803 Plus 5-FU and Leucovorin Extends Survival in Advanced Pancreatic Cancer

A recent study published in Nature highlights the potential of HR070803查看药品详情, a liposomal formulation of irinotecan查看药品详情 hydrochloride, in combination with 5-fluorouracil查看药品详情 (5-FU) and leucovorin查看药品详情, for the treatment of advanced pancreatic cancer (搜索)搜索该疾病. The study demonstrated a significant extension in overall survival (OS) among patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who had previously failed gemcitabine查看药品详情-based therapy.

The trial compared HR070803查看药品详情 plus 5-FU and leucovorin查看药品详情 to placebo plus 5-FU and leucovorin in this patient population. Results indicated a 37% reduction in the risk of death in the HR070803 group, with a median OS extension of 2.4 months compared to the placebo group. The HR070803 arm also exhibited numerically superior progression-free survival (PFS), objective response rate (ORR), time to treatment failure (TTF), and CA19-9 response.

Efficacy and Safety Profile

The efficacy of HR070803查看药品详情 combined with 5-FU and leucovorin查看药品详情 appears comparable to Onivyde查看药品详情 (nanoliposomal irinotecan查看药品详情) combined with FU and folic acid, a standard of care in this patient population, despite a lower dose of liposomal irinotecan (56.5 mg/m2 vs. 70 mg/m2). The promising efficacy of HR070803 may be attributed to the long median drug exposure time (17.4 weeks) and the small liposome particle size (approximately 80–90 nm), potentially improving drug penetration to the target tumor lesion.

The adverse event (AE) profile of HR070803查看药品详情 plus 5-FU and leucovorin查看药品详情 was manageable. Common AEs occurring more frequently (≥10%) in the HR070803 group compared to the placebo group included nausea, vomiting, diarrhea, decreased white blood cell count, decreased neutrophil count, loss of appetite, and fatigue. These AEs were consistent with those known for irinotecan查看药品详情, and no new toxicities were observed. The slow-release nature of HR070803 liposome maintains stable, lower blood concentrations of the active metabolite SN-38 and total irinotecan, resulting in relatively lower incidences of decreased neutrophil count and diarrhea compared to irinotecan hydrochloride.

Impact of UGT1A1 Polymorphism

UGT1A1 (搜索)搜索该靶点 is a crucial enzyme in irinotecan查看药品详情 metabolism, and gene mutations in the UGT1A1 gene can lead to an increased incidence of diarrhea and decreased neutrophil count caused by irinotecan. In this study, a limited number of patients with UGT1A1 mutations were included, and the polymorphism had a limited impact on neutropenia incidence.

Quality of Life Considerations

Despite the increased incidence of certain AEs associated with HR070803查看药品详情, there was no significant difference in quality of life between the HR070803 and placebo groups, suggesting that the AEs related to HR070803 combination therapy are acceptable and manageable.

Study Limitations

One limitation of this study is the small number of patients with UGT1A1 (搜索)搜索该靶点 mutations, which did not allow for the exploration of the necessity of dose adjustment of irinotecan查看药品详情 hydrochloride liposome in this population. Another limitation is the 5-FU dosing regimen, which may result in less potent outcomes when extrapolating the efficacy of this HR070803查看药品详情 combination therapy to a global population. The dose and schedule of 5-FU in both arms were chosen based on clinical practice in Chinese pancreatic cancer (搜索)搜索该疾病 patients, who generally have poor tolerance, to improve patient tolerance while ensuring efficacy.

Clinical Implications

The study concludes that HR070803查看药品详情 plus 5-FU and leucovorin查看药品详情 significantly extended OS and improved other efficacy endpoints in unresectable, locally advanced, or metastatic PDAC who have received gemcitabine查看药品详情-based therapy, compared to placebo plus 5-FU and leucovorin. The safety was acceptable and manageable, suggesting that this HR070803 combination therapy might represent a novel standard second-line treatment option for this patient population.